Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2020

Open Access 01-12-2020 | Study protocol

Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial

Authors: Zhuang Jieqin, Liu Shuling, Cai Hairong, Dai Xingzhen, Chen Yanhong, Jin Zilin, Chen Bojun

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

Coronary microvascular disease (CMVD) can be described as one of the cardiovascular diseases with normal coronary angiography but evidence of myocardial ischemia or microcirculatory lesions, often presenting as angina pectoris attacks. Coronary artery microtubular dysfunction is one of the pathogenic features of coronary heart disease, but its occurrence and development and the current CMVD-intervention therapy needs further research. Chinese traditional medicine (TCM) has advantages for the treatment of cardiovascular diseases. Hence, this article describes an ongoing randomized controlled clinical trial based on the theory of TCM for the purpose of evaluating the efficacy and safety of Guhong injection versus placebo in patients with CMVD.

Methods/design

This is a multicenter, randomized, parallel-arm, open-label, double-blind, placebo-controlled clinical trial. A total of 260 eligible patients will be allocated and randomly assigned, in a ratio of 1:1, to either the experimental group or the control group. The treatment course is 10 consecutive days, and with an 8-week follow-up. The primary outcome is therapeutic efficacy. Secondary outcomes include the quantitative score of TCM syndromes (a series of TCM symptoms and signs of coronary heart disease), the average frequency of anginal attacks, electrocardiogram (ECG) changes, inflammatory response, endothelial function indicators and myocardial metabolites.

Discussion

This trial is strictly designed in accordance with principles and regulations issued by the China Food and Drug Administration (CFDA). The results should provide high-quality evidence on the efficacy and safety of Guhong injection in the treatment of CMVD.

Trial registration

Chinese Clinical Trials Registry, ID: ChiCTR1900022902​. Registered on 27 April 2019.
Appendix
Available only for authorised users
Literature
1.
Jespersen L, Hvelplund A, Abildstrøm SZ, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734–44.CrossRef
2.
Vrints CJ, Haine SE. Prevention of coronary microvascular plugging: the next target in STEMI? EuroIntervention. 2016;12(10):1201–2.CrossRef
3.
Zhang S, Zhao Y, Xu M, et al. FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells. PLoS One. 2013;8(11):e80342.CrossRef
4.
Tong DC, Whitbourn R, MacIsaac A, et al. High-sensitivity C-reactive protein is a predictor of coronary microvascular dysfunction in patients with ischemic heart disease. Front Cardiovasc Med. 2018;4:81.CrossRef
5.
Kakuta K, Dohi K, Sato Y, et al. Chronic inflammatory disease is an independent risk factor for coronary flow velocity reserve impairment unrelated to the processes of coronary artery calcium deposition. J Am Soc Echocardiogr. 2016;29(2):173–80.CrossRef
6.
Honda A, Tahara N, Nitta Y, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography is associated with endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2016;36(9):1980–8.CrossRef
7.
Dean J, Cruz SD, Mehta PK, et al. Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol. 2015;12(7):406–14.CrossRef
8.
Jin J, Zhao Y, Fu JX. Modern clinical application of blood-activating and stasis-removing drugs in coronary heart disease. J Liaoning Univ Tradit Chin Med. 2019;21(8):32–5.
9.
Xie B, Lu YJ, Yan M. Literature textual research of the Chinese medicinal Redflower. Asia Pacific Tradit Med. 2018;14(09):58–60.
10.
Han ZR. Clinical observation of 136 cases of coronary heart disease angina pectoris treated by Guhong injection. Chin J Mod Med. 2006;8(9):78.
11.
Jiang XX, Zhao WW. The research progress in the mechanism and diagnosis of coronary microvascular disease. Med Recapitulate. 2019;25(12):2405–10.
12.
Chen XP. Clinical effect analysis of Guhong injection on coronary heart disease. World Latest Med Inf (Electronic Version). 2019;9(64):136.
13.
National Health and Pharmaceutical Bureau of China. Guidelines for clinical research on cardiovascular drugs. Chin J Clin Pharmacol. 1988;4(4):245–54.
14.
Zheng XY. Guiding principles of clinical research on Chinese medicine for treatment of coronary heart disease and angina pectoris. Beijing: China Medical Science and Technology Press; 2002. p. 69–70.
15.
Gigante B, Strawbridge RJ, Velasquez IM, et al. Analysis of the role of interleukin 6 receptor haplo-types in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease. PLoS One. 2015;10(3):e0119980.CrossRef
16.
Fortuna LA, Pawloski PA, Parker ED, et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events. Eur Heart J Cardiovasc Pharmacother. 2016;2(1):13–9.CrossRef
17.
Kolettis TM, Barton M, Langleben D, et al. Endothelin in coronary artery disease and myocardial infarction. Cardiol Rev. 2013;21(5):249–56.CrossRef
18.
Wang XF, Cui SY, Ye ZX. Research progress on the role of nitric oxide in the pathogenesis of atherosclerosis. Chin J Gerontol. 2016;36(21):5459–62.
19.
Yang XS, Sun FY, Li ZB. The value of nitric oxide, et-1 and homocysteine in the diagnosis of coronary heart disease. Lab Med. 2018;33(04):316–20.
20.
Wasserman EJ, Shipley NM. Atherothrombosis in acute coronary syndromes mechanisms, markers, and mediators of vulnerability. Mt Sinai J Med. 2006;73(1):431–9.PubMed
21.
Babllim L, Jaffea S. Troponin, the biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173(10):1191–3.CrossRef
22.
Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101–11.CrossRef
23.
Xiao WY, Huang HM, Feng LL. New research progress of coronary microvascular dysfunction. J Cardiovasc Rehabil Med. 2019;28(02):247–51.
24.
Zhong YQ, Fu JJ, Liu XM, et al. The reporting quality, scientific rigor, and ethics of randomized placebo controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials. Curr Ther Res Clin E. 2010;71:30–49.CrossRef
25.
Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.CrossRef
Metadata
Title
Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial
Authors
Zhuang Jieqin
Liu Shuling
Cai Hairong
Dai Xingzhen
Chen Yanhong
Jin Zilin
Chen Bojun
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3990-3

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue

Review

Reporting of key methodological and ethical aspects of cluster trials in hemodialysis require improvement: a systematic review

Study protocol

Comparative effectiveness of post-discharge strategies for hospitalized smokers: Study protocol for the Helping HAND 4 randomized controlled trial

Commentary

Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events

Study protocol

IMMPACT-recommended outcome measures and tools of assessment in burning mouth syndrome RCTs: an international Delphi survey protocol

Study protocol

Osteoarthritis Preoperative Package for care of Orthotics, Rehabilitation, Topical and oral agent Usage and Nutrition to Improve ouTcomes at a Year (OPPORTUNITY); a feasibility study protocol for a randomised controlled trial

Study protocol

Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial